(R)-Ketorolac((+)-Ketorolac))是酮咯酸的R-对映体作为一种口服活性物质，它是小GTP酶Cdc42和Rac1的选择性变构抑制剂，可抑制GTPase活性，通过阻断GTP结合及下游信号通路（如PAK激活）发挥作用；其功能多样，既能改变卵巢癌细胞中对侵袭和转移至关重要的行为，展现出作为卵巢癌抗转移药物的潜力，又能改善癌症相关的恶病质。

[1] Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, Wandinger-Ness A. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ther. 2015 Oct;14(10):2215-27. doi: 10.1158/1535-7163.MCT-15-0419. Epub 2015 Jul 23. PMID: 26206334; PMCID: PMC4596774.[2]Chrysostomou SE, Eder S, Pototschnig I, Mayer AL, Derler M, Mussbacher M, Schauer S, Zhang D, Yan D, Liu G, Hoefler G, Weichhart T, Vesely PW, Zhang L, Schweiger M. R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2024 Apr;15(2):562-574. doi: 10.1002/jcsm.13422. Epub 2024 Feb 1. PMID: 38302863; PMCID: PMC10995265.